Category: News
-
Gemeinsam für eine bessere Gesundheitsversorgung – LUKS Gruppe und ETH Zürich verstärken Zusammenarbeit
External article in German.
-
Teaming up for better health
External Article in English.
-
Personalized Medicine: This is happening in Switzerland
External article in German.
-
A Data-Ecosystem for Personalized Medicine
External article in German.
-
Additional Funding for PHRT Projects at PSI and Empa
Following a selection process through an international review, the PHRT Executive Committee has chosen to fund three promising projects from the ETH domain institutions, Paul Scherrer Institute (PSI) and Empa, to receive a budget envelope of CHF 1 million in total.
-
Integrated Drug Response Profiling of Myelofibrosis Patients
A recent Nature Communications paper by the Snijder & Wollscheid groups (IMSB) in collaboration with the Theocharides (USZ), Lopes (UZH), and Skoda (USB) groups, describes drugs targeting cancerous stem cells in blood of myelofibrosis patients and molecular mechanisms driving these drug responses.
-
Legal framework established for National Data Streams
SPHN and its partner initiative PHRT from the ETH Domain have reached a major milestone for the National Data Streams: for the NDS ‘LUCID’ and ‘SwissPedHealth’, the involved partners have agreed on the contractual framework conditions. They clarify the use of data within the projects and their re-use by third parties.
-
ETH Zürich and United States National Cancer Institute Sign Extension of MOU for Proteogenomics Cancer Research
The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (CPTAC) and the Switzerland International Cancer Proteogenome Consortium (ICPC) team at ETH Zürich are pleased to announce the formalization of an extension to their memorandum of understanding (MOU) for collaborative proteogenomics cancer research. This MOU serves to further strengthen the existing partnership that was established…
-
Two Clinical Trial Projects Launched: Transforming Clinical Care with ETH Technologies
Following a highly competitive selection process by an international review panel, the PHRT Executive Committee has chosen two pioneering clinical trial projects from the ETH domain, in collaboration with clinical partners, to receive substantial funding of CHF 2 million each. These projects aim to transform the standard of clinical care by harnessing the power of…
-
Fighting Blood Cancer More Efficiently
On April 20, 2023, researchers from ETH Zurich and the University Hospitals of Zurich had a publi-cation released in Nature Cancer. Their work on multiple myeloma, a blood cancer, is enabled by Prof. Dr. Berend Snijder’s Pharmacoscopy technology, which was notably developed with funding by PHRT.